



**Ischaemic Heart Disease**  
**Assessment and Management**

Eliana Reyes, MD PhD  
 Advanced Cardiac Imaging  
 Royal Brompton Hospital  
 National Heart and Lung Institute, Imperial College London  
 May 2013

Imperial College London   
 Royal Brompton & Harefield 

---

---

---

---

---

---

---

---

---

---

**Learning outcomes**

1. Understand the importance of the clinical history and physical examination in the initial assessment of patients with suspected ischaemic heart disease
2. Understand the importance of risk stratification in the management of patients with suspected or known CAD.
3. State the clinical indications for exercise ECG, non-invasive cardiac imaging and invasive coronary angiography
4. Describe the methods available for the detection of myocardial ischaemia
5. Appreciate the value of non-invasive imaging in the diagnosis of CAD
6. Understand the role of risk factor modification and pharmacological therapy in the management of patients with stable angina

---

---

---

---

---

---


---

---

---

---

**Coronary artery disease: The atherosclerotic plaque**



The diagram illustrates the Stary Classification of Atherosclerotic Plaques, showing the progression from a normal artery to an obstructive one. The stages are:

- I Normal:** Shows a healthy artery with a thin intima.
- II Early:** Shows the beginning of plaque formation with fatty streaks.
- III Lipid rich:** Shows a plaque with a lipid-rich core and a thin fibrous cap.
- IV Internal rupture:** Shows a plaque with a ruptured fibrous cap, exposing the lipid core.
- V Calcified shell:** Shows a plaque with a calcified shell over the lipid core.
- VI Calcified vulnerable plaque:** Shows a plaque with a calcified shell that is vulnerable to rupture.
- V<sub>a,b,c</sub> Rupture:** Shows a ruptured plaque with a thrombus forming on top.
- VI<sub>a,b,c</sub> Myocardial infarction:** Shows a ruptured plaque with a thrombus that has caused a myocardial infarction.
- Obstructive:** Shows a severely narrowed artery due to a large plaque and thrombus.

Labels for components and processes include: Fatty streaks, White blood cells, Calcium, Red blood cells, Lipid rich plaque, Inflammation and calcification, Scar, White blood cells, Fibrous and fibrin, and Scar development with calcification.

---

---

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**Assessment**

---

---

---

---

---

---

---

---

### Diagnosis of ischaemic heart disease

- Clinical history and physical examination

↓

- Cardiovascular risk factors
  - Diabetes
  - Hypertension
  - High cholesterol
  - Smoking
  - Family history... Others...obesity, sedentary life

---

---

---

---

---

---

---

---

### Diagnosis

- Clinical History and Physical Examination

*"Pain in his arm, in his breast and in one side of his cardia... it is death that threatens him."*

*Ebers Papyrus, 1600 B.C*



---

---

---

---


---

---

---

---

### History and diagnosis...



---

---

---

---

---

---

---

---

### Physical examination

Extent of atherosclerosis

Differential Diagnosis:

Obstructive airways disease

GI diseases

Musculoskeletal aetiology

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**Additional diagnostic tools**

- Non-invasive
  - 12-lead resting ECG
  - Exercise ECG
  - Stress cardiac imaging
  - Coronary calcium and CT Angiography (anatomical rather than functional imaging)
- Invasive
  - X-ray coronary angiography
    - IVUS
    - Fractional flow reserve measurements
    - Optical coherence tomography

LA: 4.0mm  
VA: 15.7mm  
0.85 TAP

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**Risk Stratification:**  
Importance

---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**Risk Stratification: Pre-test Probability of CAD**

Diamond and Forrester Criteria

Age (years)	Gender	Angina	Atypical CP	Non cardiac	Asympt
30-39	Men	Interm	Interm	Low	Very low
	Women	Interm	Very low	Very low	Very low
40-49	Men	High	Interm	Interm	Low
	Women	Interm	Low	Very low	Very low
50-59	Men	High	Interm	Interm	Low
	Women	Interm	Interm	Low	Very low
60-69	Men	High	Interm	Interm	Low
	Women	High	Interm	Interm	Low

---

---

---

---

---

---

---


---

---

---

**Exercise ECG**

- ✓ Physiological
- ✓ Reproduce symptoms
- ✓ Diagnostic & prognostic information



- ✓ Demanding
- ✓ Cooperation
- ✓ LBBB
- ✓ True cardiac limitation or deconditioning?

---

---

---

---

---

---

---

---

---

---

**Exercise ECG:**

**Sensitivity 68%**

**Specificity 77%**

---

---

---

---

---

---

---

---

---

---

### Southampton experience

- 1522 patients with chest pain referred Dec 97 to Apr 2000
- Clinical management decisions by SpR with consultant supervision

	Male %	Female %
Ex ECG	100	100
MPS	8	5
Angiogram	31	23
Normal angiogram	16	56

Wong. Heart 2001;85:149

---

---

---

---

---

---

---

---

### Non-invasive Cardiac Imaging

---

---

---


---

---

---

---

---



---

---

---

---

---

---


---

---



### Non-invasive Cardiac Imaging: Surrogates for Ischaemia

- Assessment of myocardial perfusion:
  - Heterogeneous distribution of blood flow
  - Techniques:
    - Myocardial perfusion scintigraphy
    - Myocardial contrast echocardiography
    - Magnetic resonance imaging (MRI)
- Assessment of contractile reserve and stress-induced regional wall motion abnormality
  - Techniques:
    - Stress echocardiography, MRI and ECG-gated SPECT




---

---

---

---




---

---

---

---

### Resting Perfusion

Myocardial distribution of tracer at rest

---

---

---

---




---

---

---

---

### Hyperaemia

Myocardial distribution of tracer following stress

---

---

---

---

---

---

---

---

### How to induce hyperaemia and ischaemia?



Physiological:

Exercise

Pharmacological:

Inotropic agents

Primary vasodilator agents

---

---

---

---

---

---

---

---

Imaging procedure	Sensitivity (%)	Specificity (%)
Exercise MPS	85-90	70-75
Pharmacological MPS	83-94	64-90
Exercise echocardiography	74-97	64-86
Dobutamine echocardiography	61-95	51-95
Perfusion CMR	84-87	58-83
Dobutamine CMR	83-89	86-96
Coronary calcium CT imaging	82-87	64-79
CT angiography	85-99	64-98

---

---

---

---


---

---

---

---

### The Ischaemic Cascade




---

---

---

---

---

---


---

---

### Patients unable to exercise

**Pharmacological Stress Agents:**

- Adenosine
- Dipyridamole
- Dobutamine
- A<sub>2A</sub> Receptor Agonists




---

---

---


---

---

---

---

---




---

---

---

---

---

---


---

---

**Heart ONLINE** Procedure guidelines for radionuclide myocardial perfusion imaging  
C. Anagnostopoulos, M. J. Harrison, A. Kellon, K. Kundley, C. Y. Loong, A. Nishi, E. Reyes, W. Tisdale and S. R. Underwood

### Indications

- To assess the presence and severity of coronary obstruction
- To aid the management of patients with CAD:
  - Risk stratification and prognosis (e.g. after MI or before non-cardiac surgery)
  - To guide strategies of revascularisation
  - To assess adequacy of revascularisation
- To assess viability and hibernation
- Special indications:
  - Anomalous coronary arteries
  - Muscle bridging
  - Kawasaki's disease



Normal Perfusion Tetrofosmin MPI

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---


---

---

---

---





---

---

---

---

---

---

---

---

### Risk Stratification Post-assessment

---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

**Management**

---

---

---

---

---

---

---

---

### Management

- Risk factor modification

– Lifestyle changes:

- Smoking cessation
- Healthy eating
- Weight loss
- Exercise
- Reduction in alcohol consumption



---

---

---

---

---

---

---

---

### Management

- Risk factor modification

- Management of other risk factors:

- Blood pressure and hypertension control
- Cholesterol - Statins
- Blood glucose and diabetes
- Antithrombotic therapy:
  - Aspirin 75 mg per day
  - Clopidogrel



---

---

---

---

---

---

---

---


### Management

- Medical therapy

– Antianginal drugs

- Beta-blockers
- Calcium antagonists
- Nitrates
- Nicorandil

– Risk factor reduction drugs (statins, aspirin)



- Mechanical revascularisation

- Percutaneous coronary procedures
- Coronary artery bypass grafting surgery



---

---

---

---

---

---

---

---